Expression of Hypoxic Marker Carbonic Anhydrase IX Predicts Poor Prognosis in Resectable Hepatocellular Carcinoma

Wei-Ju Huang1,2, Yung-Ming Jeng1,3, Hong-Shiee Lai4, Iok-U Fong1, Fang-Yu Bonnie Sheu5, Po-Lin Lai3, Ray-Hwang Yuan6,6*

1 Graduate Institute of Pathology, College of Medicine, National Taiwan University, No. 1, Jen-Ai Road, Section 1, Taipei, 10051, Taiwan, 2 Department of Nursing, Hsin-Sheng College of Medical Care and Management, No. 418, Gaoping Section, Zhongfeng Road, Longtan Township, Taoyuan County, 32544, Taiwan, 3 Department of Pathology, National Taiwan University Hospital and College of Medicine, National Taiwan University, No. 1, Jen-Ai Road, Section 1, Taipei, 10051, Taiwan, 4 Departments of Surgery, National Taiwan University Hospital and College of Medicine, National Taiwan University, No. 1, Jen-Ai Road, Section 1, Taipei, 10051, Taiwan, 5 Department of Biomedical Science, University of Illinois College of Medicine, 1601 Parkview Ave, Rockford, IL, 61107, United States of America, 6 Department of Integrated Diagnostics and Therapeutics, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, 10051, Taiwan

* d83409009@ntu.edu.tw

Abstract

Carbonic anhydrase IX (CA-IX), a hypoxia marker, correlates with tumor progression in a variety of human cancers. However, the role of CA-IX in hepatocellular carcinomas (HCCs) remains largely unknown. We examined the expression of 277 unifocal, resectable, primary HCC tumors using immunohistochemistry. The CA-IX protein was expressed in 110 of the 227 (48.5%) HCC tumors. The expression of CA-IX correlated with younger age (P = 0.0446), female sex (P = 0.0049), high serum α-fetoprotein levels (P < 1x10^-6), larger tumor size (P = 0.0031), high tumor grade (P < 1x10^-6) and high tumor stage (P = 1.5x10^-6). Patients with HCC tumors that expressed CA-IX were more likely to have lower 5-year disease-free survival (DFS; P = 0.0001) and 5-year overall survival (OS; P < 1x10^-6). The multivariate analysis indicated that CA-IX expression was an independent predictor for high tumor stage (P = 0.0044) and DFS (P = 0.0456), and a borderline predictor for OS (P = 0.0762). Furthermore, CA-IX expression predicted poor DFS and OS in patients with high tumor stage (P = 0.0004 and P < 1x10^-6, respectively). Interestingly, CA-IX expression might contribute to the worse prognosis of female patients with advanced HCCs. Our study indicates the expression of the CA-IX protein is a crucial predictor of poor prognosis in resectable HCC, and it is also an unfavorable prognostic predictor in HCC patients with high tumor stage.

Introduction

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide, particularly in Taiwan, southern China, Southeast Asia, and sub-Saharan Africa, and the incidence of HCC is
increasing in Western countries [1]. The major risk factors for HCC are hepatitis B and C, liver cirrhosis, and exposure to environmental carcinogens such as aflatoxin [2]. Although surgical resection and various methods of tumor ablation methods can be curative or prolong survival, the outcome for HCC patients remains poor. This is particularly true in patients with advanced-stage HCC because the tumor has often spread throughout the liver via the intrahepatic portal venous system, and a considerable number of HCC patients develop postoperative tumor recurrence [3]. Therefore, the identification of molecular markers that correlate with tumor progression and poor prognosis is crucial to establishing effective treatment plans for HCC patients.

Hypoxia and vascular insufficiency are frequently observed in many types of human cancers. Hypoxia plays critical roles in tumor progression by enhancing epithelial-mesenchymal transition, inducing newly formed vessels that become the main path for tumor metastasis [4,5]. In addition, hypoxia also contributes to the radio- and chemo-resistance of cancer cells [6]. In the molecular level, hypoxia induces the activation of tyrosine kinases such as Src, and the HER2/neu, IGF, and EGF receptors and stimulates the PI3K-AKT-FRAP signal transduction pathway, which leads to increase of hypoxia-induced-factor-1 (HIF-1), and thereafter enhances the transcription of target genes, such as VEGF, IGF-2, and glucose transporters; this results in increased angiogenesis, cell growth, and metabolic processes [7,8]. Moreover, HIF-1 protein binds to hypoxia-responsive element (HRE) and activates the transcription of target genes, such as GLUT1, MCT4, NHE1, VEGFA, PDGF, and carbonic anhydrase IX (CA-IX). These genes further regulate cell growth, microenvironment pH values, angiogenesis, and glucose metabolism, resulting in promotion of tumor progression [7,8].

The CA-IX protein, a direct transcriptional target of HIF-1 and one of the most prominent intrinsic markers of tumor hypoxia [9,10], has been determined to participate in numerous basic physiological functions and cancer processes [11], and can serve as a surrogate marker for the transcriptional activity of HIF-1 in solid tumors [12]. CA-IX facilitates conversion of carbon dioxide to bicarbonate ions and protons, and plays an important role in pH regulation of extracellular microenvironment, which is critical for survival of cancer cells in hypoxia and acidosis [13]. In addition, CA-IX plays an important role in cell migration [14], and its expression has been reported to be a prognostic marker for several types of cancer, including non-small cell lung cancer [15], breast cancer [16], head and neck tumors [17], bladder cancer [18], brain cancer [19], cervical cancer [20], esophageal and gastric cancer [21], rectal cancer [22], soft tissue sarcoma [23], and gallbladder cancer [24]. However, the clinical and pathological significance of CA-IX expression in human HCC remains unclear. The aims of our study were to elucidate the role of CA-IX in vascular invasion, tumor recurrence, and HCC progression, to evaluate CA-IX as a predictive biomarker for survival in HCC patients with high tumor stage.

Materials and Methods

Tissue Samples

A total of 227 unifocal, primary HCC tumors surgically resected from patients at National Taiwan University Hospital (NTUH) from July 1988 to September 1996 were used on this study retrospectively. All resected tumors underwent detailed pathological assessment, and all patients received regular follow-up examinations, as described previously [25,26]. Our study was approved by the Ethics Committee of NTUH (approval no. 201309093RIND), and all study procedures were conducted therein. All study participants provided written informed consent, which was approved by the Ethics Committee of NTUH. One teenaged male was included in our study, for whom written, informed consent was obtained from his parents. There were no other minor participants in our study. The anonymity of all patients was maintained, and all specimens were analyzed in a blinded manner. The HCC patients included 177 males and 50
females, with a mean age of 57.2 years (range, 14–88 years). Serum hepatitis B surface antigen (HBsAg) was positive in 145 (64%) patients, and hepatitis C antibody (anti-HCVs) was positive in 75 (33%) patients, 15 of which were positive for both. All patients exhibited adequate liver function reserve at the time that they received curative liver resection, and their records contained complete clinical, histopathological, and follow-up data. No patients had distant metastasis, nor had they received anticancer treatments before undergoing surgery, such as transhepatic arterial chemoembolization, percutaneous ethanol injection, radiofrequency ablation, or chemotherapy.

Histology and Tumor Staging
Surgically resected specimens were formalin fixed and paraffin embedded. Histological sections were cut at 5-μm-thickness and stained with hematoxylin-eosin. All specimens were reviewed by the same investigator (YMJ) to determine tumor grade and stage. The tumor grading was based on the criteria proposed by Edmondson and Steiner [27]. The tumors were staged according to the American Joint Committee on Cancer (AJCC) system [28] as stages I (99 cases), II (71 cases), and III (57 cases). Because the aim of our study was to evaluate the prognostic value of resectable HCCs, patients classified with stages IVA and IVB were excluded. The margins of the surgical specimens were inked and checked microscopically. Only completely resected specimens were included in our study.

Immunohistochemical Analysis of CA-IX Protein Expression.
The CA-IX protein was detected in the formalin-fixed, paraffin-embedded sections of HCC and liver tissue using a labeled streptavidin-biotin method after antigen retrieval, as previous studies [29]. The tissue sections were dewaxed and rehydrated. The antigen was retrieved by incubating the slides in 0.01 M citrate buffer (pH 6.0) at 100°C for 15 min. After blocking with 5% fetal bovine serum (FBS), the slides were incubated in a 1:100 dilution of a mouse anti-CA-IX antibody (GTX70020, GeneTex, San Antonio, TX, USA) at 4°C for 16 hours. After washed 3 times with PBS for 5 minute, the slides were incubated with a polymer-HRP reagent (BioGenex, San Ramon, CA, USA) for 30 minutes. The peroxidase activity was visualized using a diamino-benzidine tetrahydrochloride solution (BioGenex, San Ramon, CA, USA), and the slides were counterstained with hematoxylin. We replaced the primary antibody with 5% FBS as a negative control. In addition, the hepatocytes and bile ducts of the uninfected liver tissues from the surgically resected hepatic hemangiomas were used as negative and positive controls, respectively. One pathologist who was blinded to the patients’ outcomes calculated the percentage of positive cells based on 5 independent microscopic fields (× 400 magnifications) for each slide to ensure the representativeness and homogeneity of all specimens. All tumor cells within each microscopic field were counted, and the positive rate of CA-IX was calculated. For data presentation, the proportion of the tumor cells that was positive for CA-IX immunostaining were categorized as diffuse CA-IX expression (> 50%), focal or heterogeneous CA-IX expression (11–50%), or CA-IX expression in a small proportion of the tumor cells (1–10%). In the nontumorous liver, CA-IX protein was detected only in very few isolated liver cells. Hence, HCC with less than 1% of tumor cells showing immunostaining for CA-IX was regarded as negative.

Follow-up Observation Examination
All patients had been followed up for more than 5 years or until death, whichever occurred earlier. Among the 227 study patients, 93 (41%) survived longer than 5 years. Following surgery, all patients received laboratory examinations, including assessment of serum α-fetoprotein (AFP) level, at 1- to 6-month intervals, and liver ultrasonography of the liver at 3- to 12-month intervals. Computed
tomography (CT) and/or magnetic resonance imaging (MRI) were used to confirm and differentiate intrahepatic recurrence and/or distal metastasis in the patients with clinical signs of recurrence.

Depending on the tumor site, the tumor size, the number of tumors, the level of liver function, and the patient’s condition, tumor recurrence was treated by a second resection, percutaneous ethanol injection, transthoracic arterial chemoembolization, radiofrequency ablation, or chemotherapy. All patients had an equal opportunity to access all the therapeutic modalities supported by the Bureau of National Health Insurance, Taiwan.

**Statistical Analysis**

The data analyses were performed using the Epi Info computer software, version 7.1.0.6 (Centers for Disease Control and Prevention, Atlanta, GA, USA). A univariate analysis was used to examine whether the immunohistochemical marker correlated with the clinical and pathological parameters using the $\chi^2$ and Fisher’s exact tests. The cumulative survival rates after tumor resection were calculated using the Kaplan-Meier method, and the differences in the survival curves were analyzed using the log rank test. A multivariate analysis of all the parameters that were found to be significantly correlated in univariate analysis was performed using logistic regression model for tumor stage, and Cox’s proportional-hazard regression model for disease-free survival and overall survival. A two-tailed $P$ value of less than 0.05 was considered to indicate a statistically significant relationship.

**Results**

**CA-IX Protein Expression and Distribution in the HCC and Nontumorous Liver Cells**

The immunohistochemical staining was used to screen 277 HCCs to determine the frequency of CA-IX expression and the clinical and pathological significance of CA-IX expression in HCC. The CA-IX staining was predominantly membranous, with areas of concurrent cytoplasmic and nuclear staining. In the normal or nontumorous liver parenchyma, CA-IX protein was detected only in the biliary epithelial cells but not detected or detected only in very few isolated liver cells (Fig. 1A), which were defined as the negative group (117 cases, 51.5%). CA-IX protein was expressed in a small number of tumor cells in 43 cases (18.9%), focal to heterogeneous in 40 cases (17.6%; Fig. 1B), and diffuse in more than 50% tumor cells in 27 cases (11.9%; Fig. 1C), which were regarded as positive group. Moreover, in the positive group, the CA-IX protein expression was predominantly at the periphery of necrotic tumor tissue, which was consistent with the expression pattern of hypoxia markers (Fig. 1D).

**Clinical and Pathological Significance of CA-IX Expression in HCC**

To elucidate the significance of CA-IX expression in HCC, we examined possible correlations between CA-IX protein expression and major clinical and pathological features of HCC. Our preliminary analyses showed no statistically significant differences in patient survival and the association with clinical and pathological parameters among patient groups with different degrees of CA-IX expression. Therefore, we dichotomized the expression by negative ($<1\%$) and positive ($\geq 1\%$) only in the following analyses. As presented in Table 1, positive CA-IX expression in the HCCs exhibited a significant association with younger age ($\leq 56$ years; $P = 0.0446$), tended to occur in female patients ($P = 0.0049$) and correlated with high serum AFP levels ($>200$ ng/mL; $P < 1\times10^{-5}$). However, it did not correlate with other clinical parameters, such as serum HBsAg status, and anti-HCV status. Histologically, CA-IX expression exhibited a significant correlation with larger tumor size ($>3$ cm; odds ratio (OR) = $2.46$; 95% confidence interval (CI) = $1.29$–
CA-IX Expression Predicts Tumor Recurrence and Poor Prognosis

Tumor recurrence plays a crucial role in HCC patients with poor prognosis after hepatectomy [26,30]. In our series, tumor recurrence within 5 years occurred in 158 of 227 patients (69.9%).

Fig 1. Expression of CA-IX protein in non-cancerous liver parenchyma and HCC. (A and C) Immunohistochemical staining showed heterogeneous and diffuse membranous/cytoplasmic expression of CA-IX in HCC. (E) In the region of tumor necrosis, the viable tumor cells surrounding the necrotic area (N) exhibited strong CA-IX expression. (B, D, F) B, D, and F were the nontumorous counterpart of A, C, and E, respectively. They exhibited strong staining in the bile duct epithelial cells in the portal area but not in the hepatocytes or the mesenchymal cells. A-F x200 (original magnification).

doi:10.1371/journal.pone.0119181.g001
The tumor recurrent rate was approximately 1.34 times higher in the patients with CA-IX-positive HCCs than those with CA-IX-negative HCCs (80.0% vs. 59.8%; \( P = 0.0010 \)). The Kaplan-Meier survival analysis indicated that patients presenting with CA-IX-positive HCCs exhibited lower 5-year disease-free survival rate (DFS; \( P = 0.0001 \); Fig. 2A) and lower 5-year overall survival rate (OS; \( P < 1 \times 10^{-6} \); Fig. 2B) than the patients presenting with CA-IX-negative HCCs.

To identify independent factors for predicting patient survival, we put all the clinical and pathological parameters that exhibited significant correlation with high tumor stage (including age, HBsAg status, Anti-HCV status, liver cirrhosis, serumAFP levels, tumor size, and tumor grade) and significant correlation with patient survival (including age, serum AFP levels, tumor size, tumor grade, and tumor stage) in univariate analysis, and CA-IX expression in multivariate analyses. As presented in Table 2, the results indicated that larger tumor size was an independent predictor for high tumor stage (\( P = 0.0011 \)). In addition, high serum AFP levels, larger tumor size and high tumor stage were independent prognostic factors for DFS and OS (all \( P < 0.05 \)). Notably, CA-IX expression was an independent predictor for high tumor stage and DFS (\( P = 0.0047 \) and \( p = 0.0456 \), respectively), and was a borderline significant predictor for OS (\( P = 0.0762 \)).

### Table 1. Univariate analysis of CA-IX protein expression with various clinical and pathological features in 227 patients with surgically resectable primary hepatocellular carcinoma.

| Variables          | CA-IX protein expression | p value |
|--------------------|---------------------------|---------|
| **Age**            |                           |         |
| \( >56 \)          | 57 (52)                   | 1.72    |
| \( \leq 56 \)       | 53 (48)                   | (0.98–3.04) |
| **Gender**         |                           |         |
| Male               | 77 (70)                   | 2.52    |
| Female             | 33 (30)                   | (1.25–5.13) |
| **HBsAg**          |                           |         |
| Negative           | 34 (31)                   | 1.55    |
| Positive           | 76 (69)                   | (0.87–2.79) |
| **Anti-HCV**       |                           |         |
| Negative           | 77 (70)                   | 1.31    |
| Positive           | 33 (30)                   | (0.72–2.37) |
| **Cirrhosis**      |                           |         |
| No                 | 71 (65)                   | 1.18    |
| Yes                | 39 (35)                   | (0.66–2.10) |
| **μ-fetoprotein (ng/ml)** |                   |         |
| \( \leq 200 \)     | 48 (44)                   | 4.52    |
| \( >200 \)         | 62 (56)                   | (2.45–8.40) |
| **Tumor size (cm)**|                           |         |
| \( \leq 3 \)       | 21 (19)                   | 2.46    |
| \( >3 \)           | 89 (81)                   | (1.29–4.73) |
| **Tumor grade**    |                           |         |
| I–II               | 54 (49)                   | 5.03    |
| III–IV             | 56 (51)                   | (2.63–9.71) |
| **Tumor stage**    |                           |         |
| I                  | 30 (27)                   | 3.83    |
| II–III             | 80 (73)                   | (2.11–6.98) |

The tumor recurrent rate was approximately 1.34 times higher in the patients with CA-IX-positive HCCs that those with CA-IX-negative HCCs (80.0% vs. 59.8%; \( P = 0.0010 \)). The Kaplan-Meier survival analysis indicated that patients presenting with CA-IX-positive HCCs exhibited lower 5-year disease-free survival rate (DFS; \( P = 0.0001 \); Fig. 2A) and lower 5-year overall survival rate (OS; \( P < 1 \times 10^{-6} \); Fig. 2B) than the patients presenting with CA-IX-negative HCCs.

To identify independent factors for predicting patient survival, we put all the clinical and pathological parameters that exhibited significant correlation with high tumor stage (including age, HBsAg status, Anti-HCV status, liver cirrhosis, serum AFP levels, tumor size, and tumor grade) and significant correlation with patient survival (including age, serum AFP levels, tumor size, tumor grade, and tumor stage) in univariate analysis, and CA-IX expression in multivariate analyses. As presented in Table 2, the results indicated that larger tumor size was an independent predictor for high tumor stage (\( P = 0.0011 \)). In addition, high serum AFP levels, larger tumor size and high tumor stage were independent prognostic factors for DFS and OS (all \( P < 0.05 \)). Notably, CA-IX expression was an independent predictor for high tumor stage and DFS (\( P = 0.0047 \) and \( p = 0.0456 \), respectively), and was a borderline significant predictor for OS (\( P = 0.0762 \)).
Fig 2. Kaplan–Meier analyses of 5-year disease free survival (DFS) and 5-year overall survival (OS) in 227 patients with HCC. (A and B) The HCCs with CA-IX protein expression correlated with significantly lower DFS and OS than the HCCs without CA-IX protein expression ($P = 0.0001$ and $P < 1x10^{-6}$, respectively). (C and D) The combinatorial analyses revealed that CA-IX-positive high-stage HCCs had the lowest DFS ($P < 1x10^{-6}$) and OF ($P < 1x10^{-6}$), which were lower than CA-IX negative high-stage HCCs ($P = 0.0004$ and $P < 1x10^{-6}$, respectively). However, there were no differences concerning both DFS and OS in low-stage HCCs regardless presence or absence of CA-IX expression. (E and F) The female patients presenting with high-stage HCCs exhibited
Although tumor stage is the most crucial factor associated with a poor prognosis, there is heterogeneity in patient prognosis within the same stage group. Therefore, we further analyzed the prognostic role of CA-IX expression in patients with high-stage and low-stage tumors respectively. The combinatorial analysis showed that CA-IX-positive high-stage HCCs had the lowest DFS (Fig. 2C; $P < 1 \times 10^{-6}$) and OS (Fig. 2D; $P < 1 \times 10^{-6}$), significantly lower than CA-IX negative high-stage HCCs (Fig. 2C and 2D; $P = 0.0004$ and $P < 1 \times 10^{-6}$, respectively). However, there were no differences concerning DFS and OS in patients with low-stage HCCs regardless presence or absence of CA-IX expression.

Table 2. Multivariate analyses of the risk factors associated with high stage tumor, disease-free survival and overall survival of patients with surgically resectable primary hepatocellular carcinoma.

| Covariate         | Coefficient | S.E.  | Z-Statistic | O/R/H.R. (95% C.I.)           | P- value   |
|-------------------|-------------|-------|-------------|-------------------------------|------------|
| **Stage II-III†** |             |       |             |                               |            |
| Age (H/L)         | 0.4040      | 0.3292| 1.2269      | 1.4977 (0.7856–2.8556)        | 0.2199     |
| HBV (P/N)         | 0.1470      | 0.4178| 0.3519      | 1.1584 (0.5108–2.6270)        | 0.7249     |
| HCV (P/N)         | -0.1939     | 0.4271| -0.4541     | 0.8237 (0.3567–1.9024)        | 0.3497     |
| Cirrhosis (P/N)   | 0.5853      | 0.3429| 1.7070      | 1.7956 (0.9169–3.5163)        | 0.0878     |
| AFP (L/H)         | -0.3731     | 0.3437| -1.0854     | 0.6886 (0.3511–1.3507)        | 0.2777     |
| Size (S/L)        | -1.2068     | 0.3689| -3.2717     | 0.2991 (0.1452–0.6164)        | 0.0011     |
| Grade (L/H)       | -0.4763     | 0.3533| -1.3482     | 0.6211 (0.3107–1.2413)        | 0.1776     |
| CA-IX (P/N)       | 0.9435      | 0.3334| 2.8302      | 2.5689 (1.3366–4.9375)        | 0.0047     |
| **Disease-Free Survival Time‡** |             |       |             |                               |            |
| AFP (L/H)         | -0.3939     | 0.1779| -2.2149     | 0.6744 (0.4759–0.9557)        | 0.0268     |
| Size (S/L)        | -0.5155     | 0.2019| -2.5533     | 0.5972 (0.4021–0.8871)        | 0.0107     |
| Stage (L/H)       | 0.1734      | 0.1807| 0.9600      | 1.1894 (0.8347–1.6948)        | 0.3371     |
| CA-IX (P/N)       | 0.3660      | 0.1831| 1.9994      | 1.4420 (1.0072–2.0643)        | 0.0456     |
| **Overall Survival Time‡** |             |       |             |                               |            |
| AFP (L/H)         | -0.4894     | 0.1765| -2.7735     | 0.6130 (0.4338–8663)          | 0.0055     |
| Size (S/L)        | -0.6824     | 0.2377| -2.8713     | 0.5054 (0.3172–0.8053)        | 0.0041     |
| Grade (L/H)       | 0.0359      | 0.1917| 0.1870      | 1.0365 (0.7119–1.5092)        | 0.8516     |
| CA-IX (P/N)       | 0.3530      | 0.1991| 1.7729      | 1.4233 (0.9634–2.1027)        | 0.0762     |
| Stage (L/H)       | -0.9031     | 0.2049| -0.4407     | 0.4053 (0.2713–0.6057)        | <1x10⁻⁶     |

Abbreviations: S.E., Standard error; O.R., Odds ratio; H.R., Hazard ratio; C.I., Confidence interval; AFP, α-fetoprotein; L, Low or Large; H, High; S, Small; P, presence; N, absences.

† Logistic regression model
‡ Cox’s proportional hazards model

doi:10.1371/journal.pone.0119181.t002
CA-IX Expression Contributes to Poor Prognosis in Female Patients with High-Stage Tumors

As presented in Table 1, positive CA-IX expression in the HCCs exhibited a significant correlation with female gender (30% vs. 15%; \( P = 0.0049 \)). However, there were no differences in DFS and OS between female and male patients in univariate analysis. Because CA-IX expression can be used as a marker to stratify HCC patients with high-stage tumors, we further analyzed the prognostic role of CA-IX in male and female patients with high-stage HCCs. As shown in Table 3, female patients with high-stage tumors had the highest frequency to have CA-IX expression (\( P < 1 \times 10^{-6} \)), significantly higher than male patients with high-stage tumors (81.5% vs. 57.4%, \( P = 0.0385 \)), while male patients with low-stage tumors the lowest (25%). The Kaplan-Meier survival analysis indicated that female patients presenting with high-stage HCCs exhibited the lowest DFS and OS (Fig. 2E and 2F; \( P < 1 \times 10^{-6} \) and \( P < 1 \times 10^{-6} \), respectively), significantly lower than male patients presenting with high-stage HCCs (Fig. 2E and 2F; \( P = 0.0214 \) and \( P = 0.0188 \), respectively). However, there were no differences concerning DFS and OS in male and female patients with low-stage HCCs.

Discussions

Hypoxia is a major stimulus of angiogenesis, fibrogenesis, and tumor progression [31]. In clinical settings, HIF-1\( \alpha \) is considered a target for HCC therapy, and the overexpression of HIF-1\( \alpha \) is associated with poor prognosis in HCC patients [32,33]. HIF-1\( \alpha \) directly activates TWIST to promote the epithelial-mesenchymal transition and tumor metastasis [4]. Hypoxia induces the excessive accumulation of lactate and protons and deceases extracellular pH, leading to microenvironment that is conducive to the promotion of tumor motility, invasion, and metastasis [5]. A reduction in fatty acid oxidation accompanied by hypoxia may affect the progression of HCCs [34]. Moreover, tumor hypoxia is known to be associated with resistance to chemotherapy and radiotherapy [6]. CA-IX is a downstream target of HIF-1 \( \alpha \) and is a marker for tissue hypoxia. Inhibition of the major kinase pathways regulating HIF-1 resulted in abrogation of CA-IX promoter activity [35]. Kaluz et al. reported that CA-IX is one of the most sensitive endogenous sensor of HIF-1 activity due to the unique structure of CA-IX promoter and therefore CA-IX expression can represent the transcriptional activity of HIF-1 [12].

In this study, we evaluated the clinical and pathological significance of CA-IX expression in HCCs and determined that positive CA-IX expression in the HCCs exhibited a significant correlation with high serum AFP level, which is crucial clinical and histopathological risk factor for poor prognosis [30]. In addition, positive CA-IX expression also exhibited a significant correlation with high tumor grade. This finding is similar to the correlation of CA-IX expression with high tumor grade in clear cell renal cell carcinoma [36] and basal-like breast cancer [37]. Furthermore, immunohistochemical staining showed that CA-IX protein was predominantly expressed at the periphery of necrotic tumor tissue which indicates that tumor cells with CA-IX expression are more resistant to hypoxia and possess a growth advantage. Collectively, these findings indicate that CA-IX is involved in cell proliferation and differentiation, and its expression in HCC facilitates tumor cell growth and contributes to poor differentiation of the tumor cells, and hence high AFP. These findings are also consistent with our previous observations that indicated a correlation between high AFP levels and poorly differentiated HCCs [30].

Studies on CA-IX expression in HCCs are sparse. Luong-Player et al. found that CA-IX expressed focally in only 15% of HCCs and its expression may be useful in differentiating HCC from intrahepatic cholangiocarcinoma [38]. Yu et al. demonstrated that CA-IX expressed in 30.4% of HCCs, but neither the extent nor the intensity of CA-IX immunoreactivity correlate with clinicopathological variables [39]. In our study, we found that CA-IX expressed in 48.5%
of HCCs, and its expression significantly correlated with serum AFP levels, tumor size, tumor grade, tumor stage, and patient survival. Although the reasons for these discrepancies are unknown, they might be related to the quality of the antibodies, the details of the staining techniques, and the differences in the study population. In addition, the number of cases in those studies was considerably small (n = 34 and n = 69, respectively). Our study had a much larger cohort, which may make statistical significance much easier to identify. Besides, all the patients reported by Yu et al. had received TACE before surgical resection whereas we chose only patients without previous treatment as our study subjects.

In addition to being a surrogate marker of tissue hypoxia, CA-IX protein was shown to play important roles in tumor progression. Yu et al. demonstrated that the intensity of CA-IX immunoreactivity is inversely related to E-cadherin intensity [39]. They postulated that CA-IX expression may have prognostic implications in HCC patients because downregulation of E-cadherin decreases intercellular adhesion, provides the possibility of epithelial-mesenchymal transition, and results in invasiveness, metastasis and poor progression in HCC. However, they did not demonstrate the prognostic significance of CA-IX expression directly [39]. Fiaschi et al. demonstrated that cancer-associated fibroblasts increase extracellular acidity and result in metabolic reprogramming and epithelial-mesenchymal transition, motility, survival and stemness of cancer cells in prostate cancer [40]. In a recent study, CA-IX is found to be essential for the maintenance of cancer stem cells, and targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche [41]. CA-IX expression is positively correlated with resistance to chemotherapy in basal-like breast cancer [37], and is also a significant and independent prognostic indicator of overall survival and metastasis-free survival after radiation therapy in cervical cancer [20] and breast cancer [42]. On the contrary, inhibition of CA-IX activity can enhance the effect of tumor irradiation [43]. Even though the major limitation of this study is that we did not prove the mechanical association of CA-IX expression with hepatocarcinogenesis, these findings suggest possible mechanical association and provide us a rational for a new therapeutic strategy by downregulation of CA-IX expression to improve cancer therapy in HCC patients.

Tumor stage is a crucial histopathological factor in determining prognosis [44,45]. In this study, we found that CA-IX expression is an independent predictor for high-stage HCCs. Consistent with the reports regarding various human cancers [15–24], we demonstrated for the first time that CA-IX-positive HCCs were associated with significantly lower DFS and OS than CA-IX-negative HCCs in patients with resectable tumors. These findings also drove us to search for the prognostic factors in patients with high-stage HCCs. We found that patients

| Feature            | Female / H | Female / L | Male / H | Male / L | P value |
|--------------------|------------|------------|----------|----------|---------|
| CA-IX expression   |            |            |          |          |         |
| Yes                | 22 (81.5%)a,b | 11 (47.8%)a | 58 (57.4%)b | 9 (25.0%) | <1x10^-6 |
| No                 | 5 (18.5%)c | 12 (52.2%) | 43 (42.6%) | 57 (75.0%)c |

Abbreviations: H, high tumor stage; L, low tumor stage.

a, b, and c designate comparison between the indicated two groups.

P values:
a0.0275;
b0.0385;
c< 1x10^-6
with CA-IX-positive high-stage HCCs had the worst DFS and OS, significantly worse than patients with CA-IX-negative high-stage HCCs. These findings indicated that CA-IX exerted additional adverse effects on patients’ survival even in those patients with high-stage HCCs. This finding is similar to the report that CA-IX expression is an significant prognostic factor for in patients with advanced head-and-neck cancer [46]. Our results suggested that CA-IX immunostaining can divide HCCs of the same stage into different prognostic groups, and may help clinical management of patients by a more accurate prediction of patient survival, and will help us to develop better patient management strategies.

In our study, positive CA-IX expression in the HCCs exhibited a significant correlation with female patients. This finding is in accordance with the previous report by Eckert et al. that female patients show a significantly higher expression of CA-IX than male patients in oral squamous cell carcinomas [47]. Even though we did not demonstrate favorable DFS and OS in female HCC patients, female gender is a well-known prognostic factor in both treated [48] and untreated [49] HCC patients. Recently, Giannini et al. demonstrated that female gender is an independent prognostic predictor in untreated patients with advanced HCCs [50]. Interestingly, we found that female gender was a significant prognostic predictor for DFS and OS in patients with resectable advanced HCCs. In our study, we found that female patients with high-stage HCCs had the highest frequency of CA-IX expression, even higher than male patients with high-stage HCCs. We believed that, to some extent, positive CA-IX expression might contribute to the worse prognosis of female patients with resectable advanced HCCs. However, further studies were mandatory to clarify the roles of CA-IX expression in hepatocarcinogenesis in the female patients with advanced HCCs.

In conclusion, our study revealed that CA-IX expression is an important molecular predictor for postoperative tumor recurrence, and thus a prognostic indicator of unfavorable outcome, and can be a potential therapeutic target for HCC. In addition, the combinatorial analysis indicated a worse prognosis in patients with high-stage HCCs presenting CA-IX expression. Because CA-IX is an enzyme overexpressed in cancer and specific inhibitors have been developed, further studies targeting CA-IX should be performed to test the possibility of inhibiting CA-IX function for the treatment of HCC patients.

Acknowledgments
We thank Miss Eunice J. Yuan for her secretarial assistance.

Author Contributions
Conceived and designed the experiments: WJH YMJ RHY. Performed the experiments: WJH YMJ HSL. Analyzed the data: WJH YMJ HSL RHY. Contributed reagents/materials/analysis tools: IUF FYBS PLL. Wrote the paper: WJH YMJ RHY.

References
1. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology. 2002; 122: 1609–1619. PMID: 12016426
2. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet. 1999; 353: 1253–1257. PMID: 10217098
3. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer. 2003; 98: 119–127. PMID: 12833464
4. Yang MH, Wu MZ, Chiu SH, Chen PM, Chang SY, Liu CJ, et al. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol. 2008; 10: 295–305. doi: 10.1038/ncb1691 PMID: 18297062
5. Abaza M, Luqmani YA. The influence of pH and hypoxia on tumor metastasis. Expert Rev Anticancer Ther. 2013; 13: 1229–1242. doi: 10.1586/14737140.2013.843455 PMID: 24099530
6. Nurwidya F, Takahashi F, Minakata K, Murakami A, Takahashi K. From tumor hypoxia to cancer progression: the implications of hypoxia-inducible factor-1 expression in cancers. Anat Cell Biol. 2012; 45: 73–78. doi: 10.5115/acb.2012.45.2.73 PMID: 22822460

7. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med. 2002; 8: S62–67. PMID: 11927290

8. Sokkar P, Sathis V, Ramachandran M. Computational modeling on the recognition of the HRE motif by HIF-1: molecular docking and molecular dynamics studies. J Mol Model. 2012; 18: 1691–1700. doi: 10.1007/s00894-011-1150-0 PMID: 21814878

9. Pastorek J, Pastorekova S, Callebaut I, Momon JP, Zelnik V, Opavsky R, et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene. 1994; 9: 2877–2888. PMID: 8084592

10. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000; 60: 7075–7083. PMID: 11156414

11. McDonald PC, Winum JY, Supuran CT, Dedhar S. Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget. 2012; 3: 84–97. PMID: 22289741

12. Kaluz S, Kaluzová M, Liao SY, Lerman M, Stanbridge EJ. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? Biochim Biophys Acta. 2009; 1795: 167–172.

13. Ditte P, Dequiedt F, Svastova E, Hulikova A, Ohradanova-Repic A, Zatlovicova M, et al. Phosphorylation of carbonic anhydrase IX controls its ability to mediate extracellular acidification in hypoxic tumors. Cancer Res. 2011; 71: 7558–7567. doi: 10.1158/0008-5472.CAN-11-2520 PMID: 22037869

14. Svastova E, Wiatrski W, Csaderova L, Kosiš I, Skvarkova L, Hulikova A, et al. Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain. J Biol Chem. 2012; 287: 3392–3402. doi: 10.1074/jbc.M111.286062 PMID: 22170054

15. Swinson DE, Jones JL, Richardson D, Wykoff C, Turley H, Pastorek J, et al. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small lung cancer. J Clin Oncol. 2003; 21: 473–482. PMID: 12560438

16. Hussain SA, Ganesan R, Reynolds G, Gross L, Stevens A, Pastorek J, et al. Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer. Br J Cancer. 2007; 96: 104–109. PMID: 17213826

17. Troost EG, Bussink J, Kaanders JH, van Eerd J, Peters JP, Rijken PF, et al. Comparison of different methods of CAIX quantification in relation to hypoxia in three human head and neck tumor lines. Radiother Oncol. 2005; 76: 194–199. PMID: 16024110

18. Hoskin PJ, Sibtain A, Daley FM, Wilson GD. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer. 2003; 89: 1290–1297. PMID: 14520462

19. Haapasalo JA, Nordfors KM, Hilvo M, Rantalaiu J, Soini Y, Parkkila AK, et al. Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res. 2006; 12: 473–477. PMID: 16428489

20. Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wykoff CC, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 2001; 61: 6394–6399. PMID: 11522632

21. Driessen A, Landuyt W, Pastorekova S, Moons J, Goethals L, Haustermans K, et al. Expression of carbonic anhydrase IX (CA IX), a hypoxia-related protein, rather than vascular-endothelial growth factor (VEGF), a pro-angiogenic factor, correlates with an extremely poor prognosis in esophageal and gastric adenocarcinomas. Ann Surg. 2006; 243: 334–340. PMID: 16495697

22. Lee-Kong SA, Ruby JA, Chessin DB, Pucciarelli S, Shia J, Riedel ER, et al. Hypoxia-related proteins in patients with rectal cancer undergoing neoadjuvant combined modality therapy. Dis Colon Rectum. 2012; 55: 990–995. doi: 10.1097/DCR.0b013e31825bd80c PMID: 22874607

23. Maesteide K, Kandel RA, Bell RS, Catton CN, O’Sullivan B, Wunder JS, et al. Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin Cancer Res. 2004; 10: 4464–4471. PMID: 15240538

24. Liu Z, Yang Z, Jiang S, Zou Q, Yuan Y, Li J, et al. Paxillin and carbonic anhydrase IX are prognostic markers in gallbladder squamous cell adenocarcinomas and adenocarcinomas. Histopathology. 2014; 64: 921–934. doi: 10.1111/his.12341 PMID: 24354963

25. Yuan RH, Jeng YM, Chen HL, Hsieh FJ, Yang CY, Lee PH, et al. Opposite roles of human pancreatitis-associated protein and REG1A expression in hepatocellular carcinoma: association of pancreatitis-
associated protein expression with low-stage hepatocellular carcinoma, beta-catenin mutation, and favorable prognosis. Clin Cancer Res. 2005; 11: 2568–2575. PMID: 15814635

26. Yuan RH, Jeng YM, Chen HL, Lai PL, Pan HW, Hsieh FJ, et al. Stat3 inhibition cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol. 2006; 209: 549–558. PMID: 16739096

27. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954; 7: 462–503. PMID: 13160935

28. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York, NY: Springer; 2010.

29. Yuan RH, Lai HS, Hsu HC, Jeng YM, Chen HL, Lai PL, Pan HW, Hsieh FJ, et al. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol. 2006; 209: 549–558. PMID: 16739096

30. Peng SY, Chen WJ, Lai PL, Jeng YM. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer. 2004; 112: 44–50. PMID: 15305374

31. Rosmorduc O, Housset C. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis. 2010; 30: 258–270. doi: 10.1055/s-0030-1255355 PMID: 20665378

32. Dong ZZ, Yao M, Wang L, Wu W, Gu X, Yao DF. Hypoxia-inducible factor-1alpha: molecular-targeted therapy for hepatocellular carcinoma. Mini Rev Med Chem. 2013; 13: 1295–1304. PMID: 22521580

33. Li S, Yao D, Wang L, Wu W, Qiu L, Yao M, et al. Expression characteristics of hypoxia-inducible factor-1alpha and its clinical values in diagnosis and prognosis of hepatocellular carcinoma. Hepat Mon. 2011; 11: 821–828. doi: 10.5812/kowsar.1735143X.771 PMID: 22224081

34. Tanaka M, Masaki Y, Tanaka K, Miyazaki M, Kato M, Sugimoto R, et al. Reduction of fatty acid oxidation and responses to hypoxia correlate with the progression of de-differentiation in HCC. Mol Med Rep. 2013; 7: 365–370. doi: 10.3892/mmr.2012.1201 PMID: 23178736

35. Takacova M, Bullova P, Simko V, Skvarkova L, Poturnajova M, Fektecevova L, et al. Expression pattern of carbonic anhydrase IX in Medullary thyroid carcinoma supports a role for RET-mediated activation of the HIF pathway. Am J Pathol. 2014; 184: 953–965. doi: 10.1016/j.ajpath.2014.01.002 PMID: 24518567

36. Genega EM, Ghebremichael M, Najarian R, Fu Y, Wang Y, Argani P, et al. Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol. 2010; 134: 873–879. doi: 10.1309/AJCPPP857HNJMLZ PMID: 21088149

37. Tan EY, Yan M, Campo L, Han C, Takano E, Turley H, et al. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. Br J Cancer. 2009; 100: 405–411. doi: 10.1038/sj.bjc.6604844 PMID: 19165203

38. Luong-Player A, Liu H, Wang HL, Lin F. Immunohistochemical reevaluation of carbonic anhydrase IX (CA IX) expression in tumors and normal tissues. Am J Clin Pathol. 2014; 141: 219–225. doi: 10.1309/AJCPVJS28KNYZL PMID: 24436269

39. Yu SJ, Yoon JH, Lee JH, Myung SJ, Jang ES, Kwak MS, et al. Inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis. Acta Pharmacol Sin. 2011; 32: 912–920. doi: 10.1038/aps.2011.24 PMID: 21666701

40. Fiaschi T, Giannoni E, Taddei ML, Cirri P, Marin A, Pintus G, et al. Carbonic anhydrase IX from cancer-associated fibroblasts drives epithelial-mesenchymal transition in prostate carcinoma cells. Cell Cycle. 2013; 12: 1791–1801. doi: 10.4161/cc.24902 PMID: 23656776

41. Lock FE, McDonald PC, Lou Y, Serrano I, Chafe SC, Ostlund C, et al. Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche. Oncogene. 2013; 12: 1791–1801. doi: 10.4161/cc.24902 PMID: 23656776

42. Brennan DJ, Jirstrom K, Kronblad A, Millikan RC, Landberg G, Duffy MJ, et al. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance. Clin Cancer Res. 2006; 12: 6421–6431. PMID: 17085655

43. Liao SY, Darcy KM, Randall LM, Tian C, Monk BJ, Burger RA, et al. Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2010; 116: 452–458. doi: 10.1016/j.ygyno.2009.10.062 PMID: 19913895

44. Poon RT, Fan ST, Ng IO, Lo CM, Liu CL, Wong J. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer. 2000; 89: 500–507. PMID: 10931448
45. Peng SY, Ou YH, Chen WJ, Li HY, Liu SH, Pan HW, et al. Aberrant expressions of annexin A10 short isoform, osteopontin and alpha-fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma. Int J Oncol. 2005; 26: 1053–1061. PMID: 15754002

46. Bache M, Reddemann R, Said HM, Holzhausen HJ, Taubert H, Becker A, et al. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels. Int J Radiat Oncol Biol Phys. 2006; 66: 1481–1487. PMID: 17056190

47. Eckert AW, Lautner MH, Schütze A, Bolte K, Bache M, Kappler M, et al. Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. J Oral Pathol Med. 2010; 39: 313–317. doi:10.1111/j.1600-0714.2009.00829.x PMID: 19780905

48. Farinati F, Sergio A, Giacomin A, Di Nolfo MA, Del Poggio P, Benvegnù L, et al. Is female sex a significant favorable prognostic factor in hepatocellular carcinoma? Eur J Gastroenterol Hepatol. 2009; 21: 1212–1218. doi:10.1097/MEG.0b013e32831a86f8 PMID: 19465859

49. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010; 51: 1274–1283. doi:10.1002/hep.23485 PMID: 20112254

50. Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology. 2015; 61: 184–90. doi:10.1002/hep.27443 PMID: 25234419